Comprehensive, easy-to-understand information about this condition
How we create this content →The documentation for autosomal recessive spastic paraplegia type 59 is limited primarily due to its extreme rarity, affecting fewer than 1 in 1,000,000 individuals. This rarity results in a lack of systematic clinical studies and comprehensive genetic research, making it challenging to establish a clear understanding of the condition. Ongoing efforts to characterize rare diseases like SPG59 are crucial, and your experience is part of a broader need for increased awareness and research.
The clinical features of SPG59 predominantly involve the lower limbs, with spastic paraplegia reported in 80-99% of cases. Other notable symptoms include nystagmus (30-79%), talipes equinovarus (30-79%), and lower limb spasticity (30-79%). Additional features such as clonus, hyperreflexia, and limb hypertonia may also be present, affecting mobility and coordination. Intellectual disability is less common, occurring in 5-29% of individuals.
To navigate your care for autosomal recessive spastic paraplegia type 59, consider seeking a neurologist with expertise in hereditary spastic paraplegias. They can provide tailored management strategies and support. While no specific patient organizations are currently available, resources like the Genetic and Rare Diseases Information Center (GARD) at rarediseases.info.nih.gov can provide valuable information. Additionally, exploring opportunities for participation in patient registries or natural history studies may help contribute to the understanding of this condition.
Currently, there are no orphan drug designations or clinical trials specifically for autosomal recessive spastic paraplegia type 59. This absence of research activity highlights the need for increased attention and funding in the field of rare neurological disorders. For ongoing updates on potential research opportunities, you may want to monitor ClinicalTrials.gov for any future studies related to similar conditions.
Actionable guidance for navigating care for autosomal recessive spastic paraplegia type 59
To navigate your care for autosomal recessive spastic paraplegia type 59, consider seeking a neurologist with expertise in hereditary spastic paraplegias. They can provide tailored management strategies and support. While no specific patient organizations are currently available, resources like the Genetic and Rare Diseases Information Center (GARD) at rarediseases.info.nih.gov can provide valuable information. Additionally, exploring opportunities for participation in patient registries or natural history studies may help contribute to the understanding of this condition.
Consider asking your healthcare providers these condition-specific questions
Helpful links for rare disease information and support
The documentation for autosomal recessive spastic paraplegia type 59 is limited primarily due to its extreme rarity, affecting fewer than 1 in 1,000,000 individuals. This rarity results in a lack of systematic clinical studies and comprehensive genetic research, making it challenging to establish a clear understanding of the condition. Ongoing efforts to characterize rare diseases like SPG59 are crucial, and your experience is part of a broader need for increased awareness and research.
The clinical features of SPG59 predominantly involve the lower limbs, with spastic paraplegia reported in 80-99% of cases. Other notable symptoms include nystagmus (30-79%), talipes equinovarus (30-79%), and lower limb spasticity (30-79%). Additional features such as clonus, hyperreflexia, and limb hypertonia may also be present, affecting mobility and coordination. Intellectual disability is less common, occurring in 5-29% of individuals.
To navigate your care for autosomal recessive spastic paraplegia type 59, consider seeking a neurologist with expertise in hereditary spastic paraplegias. They can provide tailored management strategies and support. While no specific patient organizations are currently available, resources like the Genetic and Rare Diseases Information Center (GARD) at rarediseases.info.nih.gov can provide valuable information. Additionally, exploring opportunities for participation in patient registries or natural history studies may help contribute to the understanding of this condition.
Currently, there are no orphan drug designations or clinical trials specifically for autosomal recessive spastic paraplegia type 59. This absence of research activity highlights the need for increased attention and funding in the field of rare neurological disorders. For ongoing updates on potential research opportunities, you may want to monitor ClinicalTrials.gov for any future studies related to similar conditions.
Actionable guidance for navigating care for autosomal recessive spastic paraplegia type 59
To navigate your care for autosomal recessive spastic paraplegia type 59, consider seeking a neurologist with expertise in hereditary spastic paraplegias. They can provide tailored management strategies and support. While no specific patient organizations are currently available, resources like the Genetic and Rare Diseases Information Center (GARD) at rarediseases.info.nih.gov can provide valuable information. Additionally, exploring opportunities for participation in patient registries or natural history studies may help contribute to the understanding of this condition.
Consider asking your healthcare providers these condition-specific questions
Helpful links for rare disease information and support
The documentation for autosomal recessive spastic paraplegia type 59 is limited primarily due to its extreme rarity, affecting fewer than 1 in 1,000,000 individuals. This rarity results in a lack of systematic clinical studies and comprehensive genetic research, making it challenging to establish a clear understanding of the condition. Ongoing efforts to characterize rare diseases like SPG59 are crucial, and your experience is part of a broader need for increased awareness and research.
The clinical features of SPG59 predominantly involve the lower limbs, with spastic paraplegia reported in 80-99% of cases. Other notable symptoms include nystagmus (30-79%), talipes equinovarus (30-79%), and lower limb spasticity (30-79%). Additional features such as clonus, hyperreflexia, and limb hypertonia may also be present, affecting mobility and coordination. Intellectual disability is less common, occurring in 5-29% of individuals.
To navigate your care for autosomal recessive spastic paraplegia type 59, consider seeking a neurologist with expertise in hereditary spastic paraplegias. They can provide tailored management strategies and support. While no specific patient organizations are currently available, resources like the Genetic and Rare Diseases Information Center (GARD) at rarediseases.info.nih.gov can provide valuable information. Additionally, exploring opportunities for participation in patient registries or natural history studies may help contribute to the understanding of this condition.
Currently, there are no orphan drug designations or clinical trials specifically for autosomal recessive spastic paraplegia type 59. This absence of research activity highlights the need for increased attention and funding in the field of rare neurological disorders. For ongoing updates on potential research opportunities, you may want to monitor ClinicalTrials.gov for any future studies related to similar conditions.
Actionable guidance for navigating care for autosomal recessive spastic paraplegia type 59
To navigate your care for autosomal recessive spastic paraplegia type 59, consider seeking a neurologist with expertise in hereditary spastic paraplegias. They can provide tailored management strategies and support. While no specific patient organizations are currently available, resources like the Genetic and Rare Diseases Information Center (GARD) at rarediseases.info.nih.gov can provide valuable information. Additionally, exploring opportunities for participation in patient registries or natural history studies may help contribute to the understanding of this condition.
Consider asking your healthcare providers these condition-specific questions
Helpful links for rare disease information and support
Clinical profile data for this condition is not yet available. Phenotype information may still be loading below.
Consider asking your healthcare providers these condition-specific questions
European rare disease database
Genetic and Rare Diseases Info Center
AI-Generated Content: This summary was generated using AI. Always consult with qualified healthcare providers for medical guidance.
Kisho delivers this disease record via API, including phenotypes (HPO), genes, orphan drug designations, screening status, and PAG mapping, with version history and governance.